Herceptin approved for treatment of HER2-positive advanced stomach cancer

Published: 2010-04-05 06:59:00

Updated: 2010-04-05 06:59:00

The Korea Food and Drug Administration has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer, Roche Korea said on March 30.

The approval is based on the impressive results from the international ToGA tri...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK